Le Lézard
Classified in: Health
Subjects: CCA, TDS, FVT

Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences


SAN DIEGO, May 29, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor conferences.

Dr. Helen Torley, president and chief executive officer will represent Halozyme in a question and answer session at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes on Tuesday, June 12 at 6:20 p.m. ET / 3:20 p.m. PT.

On Wednesday, June 20, Laurie Stelzer, senior vice president and chief financial officer will represent Halozyme in a question and answer session at the 2018 JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT.

Webcasts of both sessions can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contacts:
Jim Mazzola
858-704-8122
[email protected]

Chris Burton
858-704-8352
[email protected]

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

 

SOURCE Halozyme Therapeutics, Inc.


These press releases may also interest you

at 23:03
Anti-Adhesion Products Market Projected to Reach $1.69 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

at 22:29
Juewei brand meat and vegetable products recalled due to Listeria monocytogenes
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 22:03
Contract Research Organization Services Market Projected to Reach $184.21 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

at 21:30
GREENBROOK TMS REPORTS FISCAL YEAR 2023 OPERATIONAL AND FINANCIAL RESULTS
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

at 20:25
AHF Praises Colombia for Putting Lives Before Pharma Greed
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC Deputy Registrar, Kathy Lauriente, honoured with Distinguished Service Award from Thompson Rivers University (TRU)
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

More news about Health...


News published on and distributed by: